Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India.

Clinical Lymphoma Myeloma and Leukemia(2023)10.1016/j.clml.2022.11.006Source: DataRank Database

Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India. is a research paper published in Clinical Lymphoma Myeloma and Leukemia (2023). On theSindex it has a DataRank of 0.292. It has been cited 6 times.

N/A

0.292DataRank · unranked

Scored on demand from live citation data

6 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 0.47)OA: closedTopics (32)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.292

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (7)

Reema Singh ORCID,Jyotsna Kapoor,Pritish Chandra Patra,Narendra Agrawal,Dinesh Bhurani

Live enrichment

PubMed:36566108 OpenAlex:https://openalex.org/W4309531150

Rajiv Gandhi Cancer Institute and Research Centre

FWCI

0.47

Citation Percentile

0.7%

Citation Trend

2024

2025

2026

closedLicense: https://doi.org/10.15223/policy-004

publisherhttps://api.elsevier.com/content/article/PII:S2152265022017335?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2152265022017335?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.clml.2022.11.006

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36566108

Fields of Study

Chronic Myeloid Leukemia TreatmentsDiverse Scientific Research StudiesHealth, Education, and Cultural StudiesAdultHumansAntineoplastic AgentsDasatinibImatinib MesylateIndiaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic-PhaseProtein Kinase InhibitorsRetrospective StudiesTreatment Outcome

MeSH Terms

Imatinib MesylateDasatinibAdultAntineoplastic AgentsHumansIndiaRetrospective StudiesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic-PhaseTreatment OutcomeProtein Kinase Inhibitors

Keywords

MedicineDasatinibMyeloid leukemiaInternal medicineOncologyImatinibLower Dose Dasatinib

Sustainable Development Goals

SDG 0: Good health and well-being

Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India.

FAIR Checklist

DataRank Breakdown

Authors (7)

Funding (1 grants)

Impact

Open Access

Topics